do-me/EUR-LEX huggingface dataset:
Prior notification of a concentration (Case M.10780 – WATERLAND / KIDSFOUNDATION / PARTOU) Candidate case for simplified procedure (Text with EEA relevance) 2022/C 226/04
Date: 2022-06-10
Institutions: Directorate-General for Competition, European Commission
Subjects: Netherlands, United Kingdom, child care, economic concentration, investment company, merger control








C_2022226EN.01000501.xml










10.6.2022   


EN


Official Journal of the European Union


C 226/5






Prior notification of a concentration
(Case M.10780 – WATERLAND / KIDSFOUNDATION / PARTOU)
Candidate case for simplified procedure
(Text with EEA relevance)
(2022/C 226/04)

1.   
On 2 June 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Waterland Private Equity Investments B.V. (‘Waterland’, Netherlands),










—


Orange TopCo B.V. (‘KidsFoundation/Partou’, Netherlands), jointly controlled by Waterland and Onex Corporation.




Waterland will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of KidsFoundation/Partou.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Waterland: an independent private equity investment group focusing on four investment themes: ageing population, outsourcing and efficiency, leisure and luxury, and sustainability. Waterland is mainly active in Belgium, Denmark, France, Germany, the Netherlands, Poland and the UK,










—


KidsFoundation/Partou: active in the organization and operation of childcare in the Netherlands and in the UK.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10780 – WATERLAND / KIDSFOUNDATION / PARTOU
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.
Case C-387/22: Request for a preliminary ruling from the Tribunalul Satu Mare (Romania) lodged on 10 June 2022 — Nord Vest Pro Sani Pro SRL v Administrația Județeană a Finanțelor Publice Satu Mare, Direcția Generală Regională a Finanțelor Publice Cluj-Napoca
Date: 2022-06-10
Institutions: Court of Justice
Subjects: Austria, Germany, Romania, building industry, economic activity, equal treatment, provision of services, tax exemption, tax law








C_2022368EN.01001502.xml










26.9.2022   


EN


Official Journal of the European Union


C 368/15






Request for a preliminary ruling from the Tribunalul Satu Mare (Romania) lodged on 10 June 2022 — Nord Vest Pro Sani Pro SRL v Administrația Județeană a Finanțelor Publice Satu Mare, Direcția Generală Regională a Finanțelor Publice Cluj-Napoca
(Case C-387/22)
(2022/C 368/23)
Language of the case: Romanian

Referring court

Tribunalul Satu Mare

Parties to the main proceedings


Applicant: Nord Vest Pro Sani Pro SRL

Defendants: Administrația Județeană a Finanțelor Publice Satu Mare, Direcția Generală Regională a Finanțelor Publice Cluj-Napoca

Question referred

Are the provisions of [EU] law [in question] to be interpreted as precluding or not precluding a legal situation such as that at issue in the present case, in which the Romanian legislature may treat differently, from a tax perspective, Romanian companies which conduct business on the territory of the Romanian State and those which conduct business on the territory of other Member States, with the result that the applicant company, which has provided services principally in Austria and Germany, does not benefit from the tax exemptions enjoyed by other companies in the construction sector that conduct their businesses in Romania?
Decision of the EEA Joint Committee No 168/2022 of 10 June 2022 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1868]
Date: 2022-06-10
Institutions: EEA Joint Committee
Subjects: European Economic Area, antimicrobial resistance, health control, infectious disease, market approval, marketing standard, medicinal product, pharmaceutical legislation, revision of an agreement, veterinary medicinal product




L_2022267EN.01000701.xml










13.10.2022   


EN


Official Journal of the European Union


L 267/7








            DECISION OF THE EEA JOINT COMMITTEE No 168/2022
of 10 June 2022
         
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1868]


THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,

Whereas:







(1)


Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans (1) is to be incorporated into the EEA Agreement.












(2)


Annex II to the EEA Agreement should therefore be amended accordingly,





HAS ADOPTED THIS DECISION:



Article 1
The following point is inserted after point 22f (Commission Implementing Regulation (EU) 2021/1280) of Chapter XIII of Annex II to the EEA Agreement:






‘22g.



32021 R 1760: Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans (OJ L 353, 6.10.2021, p. 1).’






Article 2
The text of Delegated Regulation (EU) 2021/1760 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.


Article 3
This Decision shall enter into force on 11 June 2022, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*), or on the day of the entry into force of Decision of the EEA Joint Committee No 371/2021 of 10 December 2021 (2), whichever is the later.


Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.




Done at Brussels, 10 June 2022.


For the EEA Joint Committee


The President

Nicolas VON LINGEN
            





(1)  
            OJ L 353, 6.10.2021, p. 1.

(*)  No constitutional requirements indicated.

(2)  
            OJ L 175, 30.6.2022, p. 48.